Bunkerhill Health vs ScreenPoint Transpara

ScreenPoint's Transpara was the AI in MASAI, the Lund University randomized trial in Swedish mammography screening, according to the vendor. ScreenPoint reports sensitivity of 80.5% against 73.8% for standard double reading at 98.5% specificity, across more than 105,000 women. The trial is Swedish and single-vendor, so how it carries over to US settings without double reading is an open question, and the 29% and 44% headline figures on the vendor page come from different analyses. Transpara has eight 510(k)s, the latest in August 2026, works on 2D and 3D mammograms and calls itself vendor agnostic. A screening program or breast imaging center reading mammograms is who it serves. Bunkerhill sells to health systems instead, as an AI agent platform with nine cleared imaging algorithms, and its customer evidence is one quote from the Chief AI Officer at UTMB Health.